Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 14, Number 6—June 2008

Dispatch

High Failure Rates of Melarsoprol for Sleeping Sickness, Democratic Republic of Congo

Jo Robays*Comments to Author , Gaspard Nyamowala†‡, Claude Sese†, Victor Betu Ku Mesu Kande†, Pascal Lutumba†§, Wim Van der Veken¶, and Marleen Boelaert*
Author affiliations: *Institute of Tropical Medicine, Antwerp, Belgium; †Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of Congo; ‡Medische Missie Samenwerking Organisation, Kinshasa; §University of Kinshasa, Kinshasa; ¶Belgian Technical Cooperation, Kinshasa;

Main Article

Table 2

Characteristics of 959 patients who experienced relapse after treatment 
with melarsoprol, Equateur Nord Province, 2001–2003

Characteristic No. (%)
Sex
M 433 (45.2)
F
526 (54.8)
Age
>1–11mo 1 (0.1)
12–59 mo 13 (1.4)
5–59 y 936 (97.6)
>60 y
9 (0.9)
Stage of disease
First 46 (4.8)
Second 782 (81.5)
Unknown
131 (13.7)
Parasites found 259 (27.0)

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO